Stay updated on CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial

Sign up to get notified when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page

  1. Check
    8 days ago
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    1.0%
    Check dated 2025-02-10T16:44:38.000Z thumbnail image
  2. Check
    15 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.1 to 2.14.2.
    Difference
    0.1%
    Check dated 2025-02-03T11:47:17.000Z thumbnail image
  3. Check
    23 days ago
    No Change Detected
  4. Check
    30 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.0 to 2.14.1.
    Difference
    0.1%
    Check dated 2025-01-20T04:11:47.000Z thumbnail image
  5. Check
    37 days ago
    Change Detected
    Summary
    The website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant change in its functionality.
    Difference
    0.2%
    Check dated 2025-01-12T23:36:10.000Z thumbnail image
  6. Check
    66 days ago
    Change Detected
    Summary
    The website has been updated from version 2.13.2 to 2.13.3.
    Difference
    0.1%
    Check dated 2024-12-15T01:21:13.000Z thumbnail image
  7. Check
    73 days ago
    Change Detected
    Summary
    The website has updated the contact details section for the study, clarifying that it now provides information for individuals who can answer questions about joining the study, along with the location details.
    Difference
    2%
    Check dated 2024-12-07T23:22:23.000Z thumbnail image

Stay in the know with updates to CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.